Litcius/Paper detail

Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial

B. Xu, Tao Sun, Q. Zhang, Ping Zhang, Zhongyu Yuan, Zefei Jiang, Xuming Wang, Shengjie Cui, Yuee Teng, X. Hu, Jingpu Yang, Hongming Pan, Zhongsheng Tong, H. Li, Qiang Yao, Y. Wang, Yongmei Yin, Ping Sun, Hong Zheng, Jing Cheng, Jinsong Lu, B. Zhang, Cuizhi Geng, Jingfeng Liu, Kunwei Shen, Shuting Yu, H. Li, Li Tang, R. Qiu

2020Annals of Oncology47 citationsDOI

Topics & Concepts

CapecitabineMedicineHazard ratioClinical endpointInternal medicineInterim analysisMetastatic breast cancerPopulationConfidence intervalBreast cancerTaxaneOncologyCancerSurgeryGastroenterologyRandomized controlled trialColorectal cancerEnvironmental healthCancer Treatment and PharmacologyBreast Cancer Treatment StudiesAdvanced Breast Cancer Therapies
Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial | Litcius